Phase 2 Breast Cancer Trial, By Invitation NCT07275463 Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, By Invitation

NCT07275463
By Invitation Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are older than 18 years of age.
  • People who have had previous testing on their primary tumour to check for estrogen receptor status (a type of hormone receptor test), and those results are available.
  • People whose blood counts and organ function fall within the required ranges — specifically: white blood cell count above 2.0 x 10⁹/L, haemoglobin above 80 g/L, and platelets above 50.0 x 10⁹/L.
  • People whose liver-related blood test results (ALT, ALP, and AST) are no more than 5 times the upper limit of the normal range, and whose bilirubin level is no more than 2 times the upper limit of normal.
  • People whose kidney function blood test (serum creatinine) is within the normal range.
  • People who are not pregnant — a negative pregnancy test is required for anyone who could potentially become pregnant. Those who are sexually active and could become pregnant must also use a medically accepted form of contraception for at least 30 days after the study ends.
  • People who are able to undergo the diagnostic tests required as part of the study.
  • People who have given their informed consent to take part.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who are currently receiving systemic cancer treatments, such as chemotherapy or targeted therapy.
  • People who have a second cancer that is not breast cancer.
  • People who currently have, or have a history of, an autoimmune disease (a condition where the immune system attacks the body).
  • People who currently have an active infection, or who have had a serious infection within the past 3 months (if considered relevant at the time of screening).
  • People who are known to be HIV positive, or who have long-term active hepatitis B or C infection.
  • People who have taken part in another clinical trial and received an experimental medication within the 30 days before screening.
  • People who are still experiencing significant side effects (above grade 2 in severity) from a previous standard or experimental treatment, according to the US National Cancer Institute's guidelines (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Phase 2
Sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
Registry
ClinicalTrials.gov
Start date
1 October 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

[99mTc]Tc-DB8 uptake in primary breast tumor; [99mTc]Tc-DB8 background uptake value; Tumor-to-background ratio (SPECT/CT)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov